Nebivolol Combix (Nebivolol)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractile force. It also stimulates nitric‑oxide production in blood‑vessel walls, causing vasodilation and decreasing peripheral resistance, which together lower arterial pressure.

The dosage of nebivolol is individualized by the prescribing clinician based on the patient’s blood‑pressure readings, age, kidney function and other health factors. The prescriber determines the appropriate strength and frequency.

Safety data for nebivolol in pregnancy and lactation are limited. It should only be used if the potential benefit justifies any possible risk to the fetus or infant, and the decision must be made by a qualified health professional.

To request Nebivolol Combix, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any required import documentation.

Nebivolol is distinguished by its β1‑selectivity combined with nitric‑oxide‑mediated vasodilation, which may result in fewer metabolic side effects and better tolerability compared with non‑selective beta blockers. However, therapeutic choice depends on individual patient characteristics and physician judgment.

Nebivolol Combix should be stored at ambient temperature, preferably below 25 °C. Keep the tablets in the original container, protect them from moisture, heat and direct sunlight to maintain potency.

Nebivolol Combix is taken orally, usually once daily with or without food, as directed by the prescribing clinician. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious adverse events, although uncommon, include marked bradycardia, severe hypotension, worsening heart‑failure symptoms, bronchospasm in patients with asthma or COPD, and rare allergic reactions such as angioedema. Patients should seek immediate medical attention if they experience these symptoms.

Nebivolol is contraindicated in patients with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, cardiogenic shock, or known hypersensitivity to nebivolol or any excipients. Caution is also advised for individuals with uncontrolled asthma, severe liver disease, or those taking interacting medications.